Beyfortus (Nirsevimab-alip) Injection 50 mg/0.5 mL, Prefilled Syringe, 0.5 mL, 5/Package
Beyfortus (nirsevimab-alip) is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in neonates and infants. This formulation is supplied as a 50 mg/0.5 mL solution in a single-dose prefilled syringe, with each package containing 5 syringes. Administered as a single intramuscular injection, it provides passive immunity against RSV.
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Beyfortus (nirsevimab-alip) is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in neonates and infants. This formulation is supplied as a 50 mg/0.5 mL solution in a single-dose prefilled syringe, with each package containing 5 syringes. Administered as a single intramuscular injection, it provides passive immunity against RSV.
1 vendor
